Results 261 to 270 of about 1,007,475 (362)

Cardiac structure and function recovery in acromegaly after treatment: insights from cardiac magnetic resonance imaging [PDF]

Yu Chen, Yangjie Li, Yu Tang, Jinhong Li, Yerong Yu, Huiwen Tan, Bowen Cai, Shu Jiang, Wei Wang, Songping Zheng, Peizhi Zhou, Wei Yi, Jiayu Sun, Yucheng Chen, Jianwei Li, Yucheng Chen, Yucheng Chen, Jianwei Li, Jianwei Li   +18 more
openalex   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

The spectrum of cardiac abnormalities in patients with acromegaly: results from a case-control cardiac magnetic resonance study [PDF]

Dario De Alcubierre, Tiziana Feola, Alessia Cozzolino, Riccardo Pofi, Nicola Galea, Carlo Catalano, Renata S. Auriemma, Rosa Pirchio, Rosario Pivonello, Andrea M. Isidori, Elisa Giannetta   +10 more
openalex   +1 more source

Real‐world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study

ESC Heart Failure, Volume 12, Issue 2, Page 1203-1216, April 2025.
The 366 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) were analyzed regarding their clinical characteristics in the first year after approval of tafamidis 61 mg for ATTR‐CM in Germany. Nearly two‐thirds of the patients were in an advanced disease stage and 64% met the key criteria of the “Transthyretin Amyloidosis ...
Richard J. Nies, Svenja Ney, Ingrid Kindermann, Yvonne Bewarder, Angela Zimmer, Fabian Knebel, Katrin Hahn, Sebastian Spethmann, Peter Luedike, Lars Michel, Tienush Rassaf, Maria Papathanasiou, Stefan Störk, Vladimir Cejka, Amin Polzin, Fabian Voss, Malte Kelm, Bernhard Unsöld, Christine Meindl, Michael Paulus, Ali Yilmaz, Bishwas Chamling, Caroline Morbach, Roman Pfister   +23 more
wiley   +1 more source

Cardiac Magnetic Resonance Imaging and Arrhythmic Risk Stratification in Cardiomyopathies. [PDF]

J Clin Med
Di Bella G, Micari A, Licordari R, Crea P, Colarusso L, Cusmà-Piccione M, Donato R, D'Angelo T, Dattilo G, Recupero A, de Gregorio C, Micari A, Donato Aquaro G.   +12 more
europepmc   +1 more source

Cardiac Magnetic Resonance in Adults: An Updated Review of the Diagnostic Approach to Major Heart Diseases. [PDF]

J Clin Med
Tudela Martínez JI, Alcaraz Pérez P, Martínez Encarnación L, González-Carrillo J, Rodríguez Sánchez D, Sarabia Tirado F, Jiménez Sánchez AF, Guzmán-Aroca F, Berna Mestre JD.   +8 more
europepmc   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Cardiac magnetic resonance as the key to uncovering unusual disseminated histoplasmosis: a case report. [PDF]

Eur Heart J Case Rep
Benzoni G, Garofani I, Artioli D, Giannattasio C, Pedrotti P.   +4 more
europepmc   +1 more source

Cardiac Functional Assessment by Magnetic Resonance Imaging

Mengdi Jiang, Minjie Lu, Shihua Zhao
openalex   +1 more source

Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator

ESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh, Katharina Koepsel, Julia W. Erath, Thomas Kuntz, Norbert Klein, Boldizsar Kovacs, Firat Duru, Ardan M. Saguner, Christian Blockhaus, Dong‐In Shin, Fabienne Kreimer, Michael Gotzmann, Hendrik Lapp, Thomas Beiert, Assem Aweimer, Andreas Mügge, Christel Weiß, Ibrahim El‐Battrawy, Ibrahim Akin   +18 more
wiley   +1 more source